VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the societe francaise des cancers de l'enfant (sfce)

Pediatric Blood and Cancer

Volumn 52, Issue 5, 2009, Pages 585-590

  Bourdeaut, Franck ^a,b,c   De Carli, Emilie ^d   Timsit, Sandra ^e   Coze, Carole ^f   Chastagner, Pascal ^g   Sarnacki, Sabine ^e   Delattre, Olivier ^c   Peuchmaur, Michel ^h   Rubie, Herve ⁱ   Michon, Jean ^a  

^a INSTITUT CURIE   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c INSTITUT CURIE   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f TIMONE HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF NANCY   (France)

^h HÔPITAL ROBERT DEBRÉ   (France)

ⁱ HÔPITAL DES ENFANTS   (France)

Author keywords

Diarrhea; Differentiation; Neuroblastoma; Vasoactive intestinal peptide; WDHA syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID; SOMATOSTATIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADJUVANT CHEMOTHERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; LABORATORY TEST; METABOLIC DISORDER; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; VERNER MORRISON SYNDROME; WEIGHT REDUCTION; DISEASE FREE SURVIVAL; ENZYMOLOGY; FEMALE; FRANCE; MALE; MEDICAL SOCIETY; METASTASIS; PATHOLOGY; RETROSPECTIVE STUDY; SECRETION; SURVIVAL RATE;

CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; INFANT; MALE; NEUROBLASTOMA; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; SURVIVAL RATE; VASOACTIVE INTESTINAL PEPTIDE;

EID: 63649122411     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21912     Document Type: Article

References (41)

1. Schotzinger RJ, Landis SC. Cholinergic phenotype developed by noradrenergic sympathetic neurons after innervation of a novel cholinergic target in vivo. Nature 1988;335:637-639.
2. Schotzinger R, Yin X, Landis S. Target determination of neurotransmitter phenotype in sympathetic neurons. J Neurobiol 1994; 25:620-639.
3. Jansen-Goemans A, Engelhardt J. Intractable diarrhea in a boy with vasoactive intestinal peptide-producing ganglioneuroblastoma. Pediatrics 1977;59:710-716.
4. Ricour C, Duhamel JF, Lesec G, et al. Choleriform diarrhea in a case of ganglioneuroblastoma. Demonstration of a high blood level of vasoactive intestinal peptide (VIP). Arch Fr Pediatr 1977;34:552-555.
5. Hansen LP, Lund HT, Fahrenkrug J, et al. Vasocative intestinal polypeptide (VIP)-producing ganglioneuroma in a child with chronic diarrhea. Acta Paediatr Scand 1980;69:419-424.
6. Kaplan SJ, Holbrook CT, McDaniel HG, et al. Vasoactive intestinal peptide secreting tumors of childhood. Am J Dis Child 1980;134:21 -24.
7. Tiedemann K, Pritchard J, Long R, et al. Intractable diarrhoea in a patient with vasoactive intestinal peptide-secreting neuroblastoma. Attempted control by somatostatin. Eur J Pediatr 1981;137:217-219.
8. Scheibel E, Rechnitzer C, Fahrenkrug J, et al. Vasoactive intestinal polypeptide (VIP) in children with neural crest tumours. Acta Paediatr Scand 1982;71:721 -725.
9. Booth IW, Fenton TR, Milla PJ, et al. A pathophysiological study of the intestinal manifestations of a vasoactive intestinal peptide, calcitonin, and catecholamine-secreting tumour. Gut 1983;24:954-959.
10. El Shafie, Samuel M, Klippel DCH, et al. Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg 1983;18:34-36.
11. Granot E, Deckelbaum RJ, Schiller M et al. Vasoactive intestinal peptide-secreting tumor appearing as growth failure. Am J Dis Child 1983;137:1203 -1204.
12. Tolia V, Dubois RS, Philippart AI et al. A case of vasoactive intestinal polypeptide secreting ganglioneuroma complicated by parasitic infestations. Am J Gastroenterol 1983;78:799-801.
13. Yamaguchi K, Abe K, Otsubo K et al. The WDHA syndrome: Clinical and laboratory data on 28 Japanese cases. Peptides 1984; 5:415-421.
14. Attat I, Podvin A, Fromentin C, et al. Chronic diarrhea caused by VIP-secreting ganglioneuroblastoma in children. Apropos of a case with areview of the literature. Chirurgie 1989;115:156 -161.
15. Davies RP, Slavotinek JP, Dorney SF. VIP secreting tumours in infancy. A review of radiological appearances. Pediatr Radiol 1990;20:504-508.
16. Kimura N, Yamamoto H, Okamoto H, et al. Multiple-hormone gene expression in ganglioneuroblastoma with watery diarrhea, hypokalemia, and achlorhydria syndrome. Cancer 1993;71:2841 -2846.
17. Murphy MS, Sibal A, Mann JR. Persistent diarrhoea and occult vipomas in children. BMJ 2000;320:1524-1526.
18. Rodriguez MM, Regalado JJ, Zaleski CG, et al. Chronic watery diarrhea in a 22-month-old girl. J Pediatr 2000;136:262-265.
19. Wildhaber B, Niggli F, Bergstrasser E, et al. Paraneoplastic syndromes in ganglioneuroblastoma: Contrasting symptoms of constipation and diarrhoea. Eur J Pediatr 2003;162:511 -513.
20. Bourgois B, Boman F, Nelken B, et al. Intractable diarrhoea revealing a neuroblastoma hypersecreting the vasoactive intestinal peptide. Arch Pediatr 2004;11:340-343.
21. Kudo K, Kitajima S, Munakata H, et al. WDHA syndrome caused by VIP-producing ganglioneuroblastoma. J Pediatr Surg 1982;17:426-428.
22. Quak SH, Prabhakaran K, Kwok R, et al. Vasoactive intestinal peptide secreting tumours in children: A case report with literature review. Aust Paediatr J 1988;24:55-58.
23. Gesundheit B, Smith CR, Gerstle JT, et al. Ataxia and secretory diarrhea: Two unusual paraneoplastic syndromes occurring concurrently in the same patient with ganglioneuroblastoma. J Pediatr Hematol Oncol 2004;26:549-552.
24. Cooney DR, Voorhess ML, Fisher JE, et al. Vasoactive intestinal peptide producing neuroblastoma. J Pediatr Surg 1982;17:821 -825.
25. Socha J, Dobrzanska A, Rowecka K, et al. Chronic diarrhea due to VIPoma in two children. J Pediatr Gastroenterol Nutr 1984;3:143-148.
26. Brunet J, Saudin F, Cochat P, et al. Metastatic neuroblastoma with secondary hypersecretion of vasoactive intestinal peptide. Pediatrie 1988;43:415 -417.
27. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: Results of the second study of the Italian Cooperative Group for Neuroblastoma. J Clin Oncol 1995;13:884-893.
28. Funato M, Fujimura M, Shimada S, et al. Rapid changes of serum vasoactive intestinal peptide after removal of ganglioneuroblas- toma with watery-diarrhea-hypokalemia-achlorhydria syndrome in a child. J Pediatr Gastroenterol Nutr 1982;1:131 -135.
29. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high- risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-1173.
30. Rubie H, Michon J, Plantaz D, et al. Unresectable localized neuroblastoma: Improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Br J Cancer 1998;77:2310-2317.
31. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-1477.
32. Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: An update in diagnosis and management in a series of 11 patients. Hepatogas- troenterology 2005;52:1259-1265.
33. Wollman Y, Lilling G, Goldstein MN, et al. Vasoactive intestinal peptide: A growth promoter in neuroblastoma cells. Brain Res 1993;624:339 -341.
34. Heraud C, Hilairet S, Muller JM, et al. Neuritogenesis induced by vasoactive intestinal peptide, pituitary adenylate cyclase-activating polypeptide, and peptide histidine methionine in SH-SY5y cells is associated with regulated expression of cytoskeleton mRNAs and proteins. J Neurosci Res 2004;75:320-329.
35. Alleaume C, Eychene A, Harnois T, et al. Vasoactive intestinal peptide-induced neurite remodeling in human neuroblastoma SH- SY5Y cells implicates the Cdc42 GTPase and is independent of Ras-ERK pathway. Exp Cell Res 2004;299:511 -524.
36. Qualman SJ, O'Dorisio MS, Fleshman DJ, et al. Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer 1992;70:2005-2012.
37. Becker H, Wirnsberger G, Ziervogel K, et al. Immunohistochem- ical markers in (ganglio)neuroblastomas. Acta Histochem Suppl 1990;38:107 -114.
38. Mendelsohn GEJ, Olson JL, Said SI, et al. Vasoactive intestinal peptide and its relationship to ganglion cell differentiation in neuroblastic tumors. Lab Invest 1979;41:144-149.
39. Waschek JA, Lelievre V, Bravo DT, et al. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines. Peptides 1997;18:835-841.
40. Handler A, Lobo MD, Alonso FJ, et al. Functional implications of the noradrenergic-cholinergic switch induced by retinoic acid in NB69 neuroblastoma cells. J Neurosci Res 2000;60:311 -320.
41. Wirnsberger GH, Becker H, Ziervogel K, et al. Diagnostic immunohistochemistry of neuroblastic tumors. Am J Surg Pathol 1992;16:49-57.